Drugs / NA-931
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06615700 | May → Aug 2024 | obesity disorder, type 2 diabetes mellitus | Biomed Industries, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06564753 | Jul 2024 → Feb 2025 | obesity disorder | Biomed Industries, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06732245 Comparator | Aug 2026 → Aug 2027 expected | obesity disorder | Biomed Industries, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NA-931 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06564753 ↗ |
| Action | Activate | “NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist” NCT06564753 ↗ |
| Modality | Peptide | “NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist” NCT06564753 ↗ |
| Route | Oral | “NA-931 dose 1, daily and orally” NCT06564753 ↗ |